Mexico Hypersomnia Therapeutics Market Analysis

Mexico Hypersomnia Therapeutics Market Executive Summary

The Mexico Hypersomnia Therapeutics Market is at around $13.80 Mn in 2023 and is projected to reach $18.78 Mn in 2030, exhibiting a CAGR of 4.5% during the forecast period.

Hypersomnia is a group of neurological disorders characterized by excessive daytime sleepiness, despite getting enough sleep at night. This can significantly impair daily functioning and reduce quality of life. While the exact causes are still being researched, hypersomnia can be linked to underlying medical conditions, neurological disorders, or disruptions in sleep regulation mechanisms. People with hypersomnia often experience symptoms such as not feeling refreshed upon waking, feeling groggy and slow for extended periods after waking, and an excessive need for sleep despite sleeping for long periods. Chronic headaches, loss of appetite, excessive sweating, and depression have also been reported. Treatment for hypersomnia focuses on managing daytime sleepiness. This can involve adopting healthy lifestyle practices like eating well and exercising regularly. Medications like stimulants can also be prescribed to promote wakefulness. In some cases, cognitive behavioral therapy for insomnia (CBT-I) can help address underlying sleep habits that contribute to hypersomnia.

The prevalence of excessive daytime sleepiness, a key symptom of hypersomnia, is 20.9% among the people of Mexico. The market therefore is driven by significant factors like the increasing awareness about hypersomnia disorders, rising aging population, and technological advancements. However, limited treatment options, limited accessibility to specialized healthcare services, and potential side effects restrict market growth.

The leading pharmaceutical companies include Sanofi and Novartis. Takeda Pharmaceuticals, Laboratorios Sanfer, and Merck are also significant contributors to the hypersomnia therapeutics landscape, with continuous research and development activities.

Market Dynamics

Market Growth Drivers

Increasing Awareness about Hypersomnia Disorders: Increased public awareness campaigns and healthcare professional education are leading to more accurate diagnoses, raising the potential patient pool for these medications. “Mass Nap" event was organized by the Center for Sleep and Neurosciences and the Mexican Society for the Investigation of Medicine and Sleep (SOMIMS) to raise awareness about the importance of sleep.

Expanding Geriatric Population: Hypersomnia may be more common in older adults due to changes in sleep structure and health conditions. Older adults currently represent 8% of the population, and the prevalence of hypersomnia is expected to increase, creating a demand for effective treatment options to meet the unique needs of older adults.

Technological Advancements: Ongoing technological advancements are fuelling the market, improving the efficiency and effectiveness of Hypersomnia Treatment products and services. Pharmaceutical companies are investing in research and development to create newer and more effective medications for hypersomnia.

Market Restraints

Limited Treatment Options: The selection of hypersomnia drugs is relatively small. This dearth of choices proves particularly problematic for patients who exhibit varying degrees of symptom severity or respond differently to different medications. As a result, healthcare providers struggle to find the most suitable treatment regimen for individual patients, leading to suboptimal outcomes and patient dissatisfaction.

Limited Accessibility to Specialized Healthcare Services: Rural Mexicans face challenges in accessing specialized care for hypersomnia. Sleep clinics, neurologists, and sleep specialists, all knowledgeable about sleep disorders, tend to cluster in urban areas. The absence of hypersomnia experts in rural areas hampers affected individuals.

Potential Side Effects: Hypersomnia drugs can relieve extreme drowsiness but may produce unwanted consequences. These side effects can discourage some people from undergoing treatment or discontinuing it prematurely. The quality of life for people with hypersomnia is negatively affected, and the pharmaceutical industry faces a growth challenge as a result.

Regulatory Landscape and Reimbursement Scenario

Mexico's pharmaceutical market is overseen by the Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS). It is responsible for the entire drug approval process, ensuring the safety and efficacy of medications available in Mexico.

A comprehensive dossier containing all necessary data and documentation about the drug is submitted to COFEPRIS. It evaluates the dossier and may request additional information or clarifications from the applicant. After a thorough review, COFEPRIS issues a decision to either approve or reject the application for registration.

The Mexican Institute of Social Security is a governmental organization that assists public health, pensions, and social security in Mexico operating under the Secretariat of Health. There is no direct reimbursement scheme in Mexico. The government covers the costs through contributions from employers, employees, and general taxation.

Competitive Landscape

Key Players

Here are some of the major key players in the Mexico Hypersomnia Therapeutics Market:

• Sanofi
• Takeda Pharmaceuticals
• Novartis
• Pfizer
• Merck
• Teva Pharmaceuticals
• AstraZeneca
• Laboratorios Senosiain
• Laboratorios Sanfer
• Theranexus